Friday, July 10, 2026

Drug profile · INN

thiethylperazine maleate

thiethylperazine maleate (TORECAN) is a dopamine d2 receptor antagonist. Route of administration: rectal. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — thiethylperazine maleate
US status
approved
Class
Route
RECTAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

thiethylperazine maleate (TORECAN) is a dopamine d2 receptor antagonist. Route of administration: rectal. Current US regulatory status: approved.

Key facts

INN thiethylperazine maleate
Brand TORECAN
Mechanism Dopamine D2 receptor antagonist
Target D(2) dopamine receptor
Route RECTAL
Formulation SUPPOSITORY

Mechanism of action

Dopamine D2 receptor antagonist

Primary target: D(2) dopamine receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. cabergoline Dopamine D2 receptor agonist
  4. clozapine Serotonin 2a (5-HT2a) receptor antagonist
  5. fluphenazine decanoate Dopamine D2 receptor antagonist
  6. fluphenazine hydrochloride Dopamine D2 receptor antagonist

Frequently asked questions

What is thiethylperazine maleate?

thiethylperazine maleate (TORECAN) is a dopamine d2 receptor antagonist. Route of administration: rectal. Current US regulatory status: approved.

What is the brand name for thiethylperazine maleate?

TORECAN is a marketed brand name for thiethylperazine maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of thiethylperazine maleate?

thiethylperazine maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.